Research Papers:
MicroRNA-610 suppresses osteosarcoma oncogenicity via targeting TWIST1 expression
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1487 views | HTML 2529 views | ?
Abstract
Chi Jin1,*, Yongjian Feng2,*, Yongjian Ni1 and Zhonglin Shan1
1The Third Department of Orthopaedics, Central Hospital of Cangzhou City, Cangzhou, Hebei, China
2The Fourth Department of Orthopaedics, Central Hospital of Cangzhou City, Cangzhou, Hebei, China
*These authors contributed equally to this work
Correspondence to:
Chi Jin, email: [email protected]
Keywords: osteosarcoma, microRNAs, miR-610, Twist1, cisplatin
Received: January 16, 2017 Accepted: March 24, 2017 Published: April 11, 2017
ABSTRACT
Osteosarcoma is the most frequent primary bone tumor affects adolescents and young adults. Recently, microRNAs (miRNAs) are short, non-coding and endogenous RNAs that played as important roles in the initiation and progression of tumors. In this study, we try to explore the biological function and expression of miR-610 in the osteosarcoma. We showed that miR-610 expression was downregulated in the osteosarcoma tissues and cell lines. Elevated expression of miR-610 suppressed the osteosarcoma cell proliferation, cell cycle, invasion and EMT program. Moreover, overexpression of miR-610 increased sensitivity of MG-63 and U2OS cells to cisplatin. Twist1 was identified as a direct target gene of miR-610 in the osteosarcoma cell. Furthermore, we demonstrated that Twist1 was upregulated in the osteosarcoma tissues and cell lines. The expression of Twist1 was negatively associated with the expression of miR-610 expression in the osteosarcoma tissues. Ectopic expression of Twist1 inhibited the sensitivity of miR-610-overexpressing MG-63 cells to cisplatin. We also showed that overexpression of Twist1 increased the proliferation and invasion of miR-610-overexpressing MG-63 cells. These data indicated that ectopic expression of miR-610 suppressed the osteosarcoma cell proliferation, cell cylce, invasion and increased the sensitivity of osteosarcoma cells to cisplatin through targeting the Twist1 expression.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 17045